Autologous hematopoietic stem cells (HSCs)

Autologous hematopoietic stem cells (HSCs) are multipotent, self-renewing cells derived from the patient's own body, typically harvested from peripheral blood after mobilization or directly from bone marrow (StatPearls, 2023). These cells are characterized by the expression of the CD34 surface marker and the ability to differentiate into all blood cell lineages, including myeloid and lymphoid cells (NIH, 2024). In clinical practice, they are the cornerstone of autologous hematopoietic stem cell transplantation (ASCT), which is used to rescue the hematopoietic system following high-dose, myeloablative chemotherapy for malignancies such as multiple myeloma and relapsed lymphomas (American Society of Hematology, 2023). Beyond oncology, autologous HSCs serve as the substrate for transformative gene therapies, where they are genetically modified ex vivo—using viral vectors or CRISPR/Cas9—to treat inherited disorders like sickle cell disease and beta-thalassemia (Nature Medicine, 2022). Drugs such as filgrastim and plerixafor interact with the HSC niche to facilitate the mobilization of these cells into circulation for collection (PubMed, 2021). Following re-infusion, these cells must home to the bone marrow and engraft to restore long-term hematopoiesis, a process monitored by the recovery of neutrophil and platelet counts (Journal of Clinical Oncology, 2022). Therapeutic challenges include the risk of graft failure, the presence of clonal hematopoiesis, and the toxicities associated with the conditioning regimens required to make space in the marrow (Blood, 2023).

Other names

Autologous HSCsCD34+ cellsPatient-derived hematopoietic stem cellsSelf-derived blood stem cellsAutologous blood stem cells

Autologous hematopoietic stem cells are harvested from a patient, typically after mobilization from the bone marrow into peripheral blood via G-CSF or CXCR4 inhibitors, and are re-infused following high-dose chemotherapy or ex vivo genetic modification to restore functional blood cell production (StatPearls, 2023; FDA, 2023).